z-logo
Premium
Normal tissue dose conformality measures to guide radiotherapy fractionation decisions
Author(s) -
Myerson Robert J.
Publication year - 2011
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.3560417
Subject(s) - fractionation , context (archaeology) , nuclear medicine , radiation therapy , therapeutic index , dosimetry , dose fractionation , constraint (computer aided design) , mathematics , medicine , radiology , chemistry , biology , paleontology , geometry , drug , organic chemistry , psychiatry
Purpose: To determine conditions under which hypofractionation could be favorable for a normal tissue—even if tumor[ α / β ]exceeds the normal tissue's[ α / β ] .Methods: The hypofractionation sufficiency condition (HSC) for an organ is defined as a dose conformality constraint such that, if satisfied, a family of tumor control probability isoeffective fractionation schemes will show decreasing normal tissue complication probability with decreasing number of fractions.Results: In the extended equivalent uniform dose (EUD) model [obtained by replacing dose with linear quadratic (LQ) 2 Gy equivalent dose], the HSC for a normal organ is proven to be satisfied if a suitably weighted average of the relative dose [hypofractionation sufficiency index (HSI)] is less than the ratio of normal tissue to tumor[ α / β ] . The HSI is determined solely by dose distribution and the normal tissue volume factor, “ a .” If the HSC is satisfied for every normal tissue of concern, then there is a therapeutic gain with hypofractionation. The corresponding multifractionation sufficiency condition (therapeutic gain with increasing number of fractions) and multifractionation sufficiency index (MSI) are also derived. A sample clinical case is presented.Conclusions: Within the context of the LQ/EUD models, conformality measures (HSI and MSI) can be used to inform fractionation decisions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here